Press and Announcements

Please check back frequently for news, announcements, and events.

 

Homepage-Pipeline

ipeline Praetego’s novel small molecules (Amadorins) have demonstrated preclinical proof of mechanism in a variety of AGE-driven disease models. Our pipeline includes programs for Neuropathy, Retinopathy, and Neurodegeneration / Alzheimer’s Disease. Read More >